Agilent Technologies (NYSE:A) Given "Hold (C)" Rating at Weiss Ratings

Key Points

• Agilent Technologies received a "hold (C)" rating from Weiss Ratings, while several other analysts have upgraded the stock to "buy" or "strong buy" ratings in recent weeks.
• The company's stock has seen target price increases from various firms, with UBS raising it to $170.00 and JPMorgan Chase to $165.00, reflecting investor confidence.
• Agilent's recent earnings report indicated 10.1% revenue growth year-over-year, with earnings per share meeting consensus estimates at $1.37.

Agilent Technologies (NYSE:A - Get Free Report)'s stock had its "hold (c)" rating reissued by equities research analysts at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

A has been the subject of several other reports. Rothschild Redb upgraded shares of Agilent Technologies to a "strong-buy" rating in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of Agilent Technologies from a "hold" rating to a "buy" rating in a report on Friday, October 3rd. Evercore ISI increased their target price on shares of Agilent Technologies from $128.00 to $140.00 and gave the stock an "in-line" rating in a report on Tuesday, October 7th. UBS Group upgraded shares of Agilent Technologies from a "neutral" rating to a "buy" rating and increased their target price for the stock from $130.00 to $170.00 in a report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. increased their target price on shares of Agilent Technologies from $155.00 to $165.00 and gave the stock an "overweight" rating in a report on Thursday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $149.62.

Agilent Technologies Price Performance

A traded up $0.64 during trading on Friday, reaching $148.10. The stock had a trading volume of 452,757 shares, compared to its average volume of 1,914,461. The stock has a market cap of $41.99 billion, a PE ratio of 34.74, a PEG ratio of 4.76 and a beta of 1.26. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.71 and a current ratio of 2.25. Agilent Technologies has a one year low of $96.43 and a one year high of $153.84. The business has a 50-day moving average of $129.81 and a 200-day moving average of $118.86.

Agilent Technologies (NYSE:A - Get Free Report) last posted its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.37. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.67 billion. During the same period in the prior year, the business posted $1.32 earnings per share. The company's revenue was up 10.1% on a year-over-year basis. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, equities research analysts anticipate that Agilent Technologies will post 5.58 EPS for the current fiscal year.

Hedge Funds Weigh In On Agilent Technologies

Several large investors have recently made changes to their positions in A. Brighton Jones LLC lifted its holdings in shares of Agilent Technologies by 6.1% during the fourth quarter. Brighton Jones LLC now owns 4,663 shares of the medical research company's stock valued at $626,000 after purchasing an additional 270 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Agilent Technologies by 34.6% during the first quarter. GAMMA Investing LLC now owns 5,362 shares of the medical research company's stock valued at $627,000 after acquiring an additional 1,379 shares in the last quarter. Asset Management One Co. Ltd. increased its position in shares of Agilent Technologies by 6.3% during the first quarter. Asset Management One Co. Ltd. now owns 120,425 shares of the medical research company's stock valued at $14,087,000 after acquiring an additional 7,166 shares in the last quarter. Sequoia Financial Advisors LLC increased its position in shares of Agilent Technologies by 3.3% during the first quarter. Sequoia Financial Advisors LLC now owns 35,004 shares of the medical research company's stock valued at $4,095,000 after acquiring an additional 1,106 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. increased its position in shares of Agilent Technologies by 2.1% during the first quarter. Robeco Institutional Asset Management B.V. now owns 78,679 shares of the medical research company's stock valued at $9,204,000 after acquiring an additional 1,614 shares in the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.